1327: Gene Expression Profiles in Benign Prostatic Hyperplasia

2004 ◽  
Vol 171 (4S) ◽  
pp. 349-350
Author(s):  
Gaelle Fromont ◽  
Michel Vidaud ◽  
Alain Latil ◽  
Guy Vallancien ◽  
Pierre Validire ◽  
...  
Keyword(s):  
Gene Expression ◽  
Benign Prostatic Hyperplasia ◽  
Expression Profiles ◽  
Gene Expression Profiles ◽  
Prostatic Hyperplasia

scholarly journals miRNA Regulation Network Analysis in Qianliening Capsule Treatment of Benign Prostatic Hyperplasia

2015 ◽  
Vol 2015 ◽  
pp. 1-9 ◽  
Author(s):  
Liya Liu ◽  
Yun Wan ◽  
Aling Shen ◽  
Jinyan Zhao ◽  
Jiumao Lin ◽  
...  
Keyword(s):  
Gene Expression ◽  
Cell Proliferation ◽  
Benign Prostatic Hyperplasia ◽  
Network Analysis ◽  
Signaling Pathways ◽  
Expression Profiles ◽  
Prostatic Hyperplasia ◽  
Differentially Expressed ◽  
Epithelial Cell Line ◽  
Mirna Regulation

Objective. The objective of this study was to evaluate the molecular mechanism by which Qianliening capsule (QC) treats benign prostatic hyperplasia (BPH).Methods. Benign prostatic hyperplasia epithelial cell line BPH-1 was treated with 0, 1.25, 2.5, and 5 mg/mL QC for 48 h, respectively. Evaluation of cell viability and observation of morphologic changes of BPH-1 cell gene expression and miRNA expression profiles were analyzed. Real-time quantitative PCR was used to confirm changes in miRNA and gene expression. GO and KEGG pathway-based approaches were used to investigate biological functions and signaling pathways affected by differentially expressed mRNAs.Results. QC inhibited BPH-1 cell proliferation. Differential expression of 19 upregulated and 2 downregulated miRNAs was observed in QC-treated BPH-1 cells compared to untreated control cells. 107 upregulated and 71 downregulated genes were identified between the two groups. Significantly enriched signaling pathways based on deregulated mRNAs were mainly involved in regulation of cell proliferation, apoptosis, and so on. Additionally, miRNA-mRNA network analysis integrated these miRNAs and genes by outlining interactions of miRNA and related genes.Conclusion. The study was the first report of differentially expressed miRNA and mRNA in QC-treated BPH-1 cells.

Development of Quantitative Detection Assays for CYR61 as a New Marker for Benign Prostatic Hyperplasia

2003 ◽  
Vol 8 (6) ◽  
pp. 701-711 ◽  
Author(s):  
Shinji Sakamoto ◽  
Masahiro Yokoyama ◽  
Kulkarni Prakash ◽  
Jun-Ichiro Tsuruha ◽  
Satoshi Masamoto ◽  
...  
Keyword(s):  
Gene Expression ◽  
Benign Prostatic Hyperplasia ◽  
Expression Profiles ◽  
Prostatic Hyperplasia ◽  
Early Gene ◽  
Detection Methods ◽  
Morbidity Rate ◽  
Quantitative Detection ◽  
High Morbidity ◽  
High Morbidity Rate

Among urological diseases, benign prostatic hyperplasia (BPH) exhibits a high morbidity rate, afflicting approximately 50% of men older than age 50 years. Despite intense research efforts over the past decades, the etiology and mechanisms of BPH progression are only poorly understood. Employing oligonucleotide microarrays, the authors analyzed the gene expression profiles in normal and BPH prostate samples and found that CYR61, an immediate early gene, is markedly overexpressed in BPH. To quantify cellular CYR61 mRNA expression directly, the authors developed an assay using branched-chain DNA (bDNA) technology. A human prostatic epithelial cell line, BRF-55T, derived from a BPH patient, was treated with fetal bovine serum to stimulate gene expression, and then the induction profile of the CYR61 mRNA in these serum-stimulated cells was quantitated using both bDNA and quantitative reverse transcriptase–PCR (RT-PCR). The results obtained with the 2 detection systems were found to be very similar. The bDNA assay was also found to be sensitive and highly reproducible. To the authors’knowledge, this is the first time that identifying CYR61 as a novel marker for BPH and its quantitation has been reported. These detection methods not only may be useful for diagnostic purposes but may also be used to identify suppressors of CYR61 expression for BPH therapy employing high-throughput screening assays.

Sign in / Sign up

Export Citation Format

Share Document